Ivan Foeldvari1, Jens Klotsche2, Kathryn S Torok3, Ozgur Kasapcopur4, Amra Adrovic4, Valda Stanevicha5, Maria Teresa Terreri6, Ekaterina Alexeeva7, Maria Katsicas8, Rolando Cimaz9, Mikhail Kostik10, Thomas Lehman11, Walter-Alberto Sifuentes-Giraldo12, Vanessa Smith13, Flavio Sztajnbok14, Tadej Avcin15, Maria Jose Santos16, Monika Moll17, Dana Nemcova18, Cristina Battagliotti19, Despina Eleftheriou20, Mahesh Janarthanan21, Tilmann Kallinich22, Jordi Anton23, Kirsten Minden2,22, Susan Nielsen24, Yosef Uziel25, Nicola Helmus1. 1. Hamburg Centre for Pediatric and Adolescent Rheumatology, Schön Klinik Hamburg Eilbek, Hamburg, Germany. 2. German Rheumatism Research Center, Berlin, Germany. 3. Children's Hospital of Pittsburgh, Pittsburgh, PA, USA. 4. Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey. 5. University Children's Hospital, Riga, Latvia. 6. Universidade Federal de São Paulo, Sao Paulo, Brazil. 7. Scientific Center of Children's Health, Moskva, Russia. 8. Hospital de Pediatria, Buenos Aires, Argentine. 9. Meyer Children's Hospital, Florence, Italy. 10. Federal State Autonomous Institution "National Medical Research Center of Children's Health" of the Ministry of Health of the Russian Federation, Moscow, Russia. 11. Hospital for Special Surgery, New York, NY, USA. 12. University Hospital Ramón y Cajal, Madrid, Spain. 13. Department of Internal Medicine, Ghent University, Ghent, Belgium. 14. Universidade do Estado, Rio de Janeiro, Brazil. 15. University Children's Hospital Ljubljana, Ljubljana, Slovenia. 16. Serviço de Reumatologia, Hospital Garcia de Orta, Almada, Portugal. 17. Pediatric Rheumatology, University Tübingen, Tübingen, Germany. 18. Department of Pediatrics and Adolescent Medicine, University Childrens Hospital, Prague, Czech Republic. 19. Hospital de Niños Dr. Orlando Alassia, Santa Fee, Argentine. 20. Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK. 21. Pediatric Rheumatology, Sri Ramachandra University, Chennai, India. 22. Division of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany. 23. Hospital Sant Joan de Déu Barcelona, Barcelona, Spain. 24. Rigshospitalet, Copenhagen, Denmark. 25. Meir Medical Center, Tel Aviv University, Kfar Saba, Israel.
Abstract
Introduction: Juvenile systemic sclerosis is an orphan disease. Currently, the majority of juvenile systemic sclerosis cohort studies are retrospective in design without standardized assessment. This study was conducted prospectively to investigate the difference in manifestations of limited cutaneous juvenile systemic sclerosis and diffuse cutaneous juvenile systemic sclerosis subtypes. An additional aim was to compare these data to other juvenile systemic sclerosis cohorts and a large adult systemic sclerosis cohort. Methods: Patients fulfilling the Paediatric Rheumatology European Society juvenile systemic sclerosis classification criteria were included. Clinical characteristics and patient-related outcomes were assessed. Results: In all, 88 patients with a mean disease duration of 3.5 years were enrolled, 72.5% with diffuse cutaneous juvenile systemic sclerosis with a mean modified Rodnan Skin score of 18 and 27.5% with limited cutaneous juvenile systemic sclerosis with mean modified Rodnan Skin score of 9. The mean age at the onset of Raynaud's and first non-Raynaud's symptoms was similar in both groups, approximately 9 and 10.5 years. Active digital tip ulcerations were present in 29% diffuse cutaneous juvenile systemic sclerosis and none in the limited cutaneous juvenile systemic sclerosis subjects (p = 0.005). Of those with cardiopulmonary testing, 3% of diffuse cutaneous juvenile systemic sclerosis and 23% of limited cutaneous juvenile systemic sclerosis group had cardiac involvement (p = 0.015), and 41% diffuse cutaneous juvenile systemic sclerosis and 22% of the limited cutaneous juvenile systemic sclerosis group had pulmonary involvement (p = 0.009). Physician global disease damage assessment was higher in the diffuse cutaneous juvenile systemic sclerosis group compared to the limited cutaneous juvenile systemic sclerosis group: 35 and 15 (p = 0.021). Discussion: The majority of this international juvenile systemic sclerosis cohort had diffuse cutaneous juvenile systemic sclerosis (72.5%) with more frequent vascular and pulmonary involvement compared to the limited cutaneous group, who had increased cardiac involvement. Our cohort reflects prior findings of published juvenile systemic sclerosis cohorts and emphasizes a difference in the presentation compared to adult-onset systemic sclerosis.
Introduction: Juvenile systemic sclerosis is an orphan disease. Currently, the majority of juvenile systemic sclerosis cohort studies are retrospective in design without standardized assessment. This study was conducted prospectively to investigate the difference in manifestations of limited cutaneous juvenile systemic sclerosis and diffuse cutaneous juvenile systemic sclerosis subtypes. An additional aim was to compare these data to other juvenile systemic sclerosis cohorts and a large adult systemic sclerosis cohort. Methods: Patients fulfilling the Paediatric Rheumatology European Society juvenile systemic sclerosis classification criteria were included. Clinical characteristics and patient-related outcomes were assessed. Results: In all, 88 patients with a mean disease duration of 3.5 years were enrolled, 72.5% with diffuse cutaneous juvenile systemic sclerosis with a mean modified Rodnan Skin score of 18 and 27.5% with limited cutaneous juvenile systemic sclerosis with mean modified Rodnan Skin score of 9. The mean age at the onset of Raynaud's and first non-Raynaud's symptoms was similar in both groups, approximately 9 and 10.5 years. Active digital tip ulcerations were present in 29% diffuse cutaneous juvenile systemic sclerosis and none in the limited cutaneous juvenile systemic sclerosis subjects (p = 0.005). Of those with cardiopulmonary testing, 3% of diffuse cutaneous juvenile systemic sclerosis and 23% of limited cutaneous juvenile systemic sclerosis group had cardiac involvement (p = 0.015), and 41% diffuse cutaneous juvenile systemic sclerosis and 22% of the limited cutaneous juvenile systemic sclerosis group had pulmonary involvement (p = 0.009). Physician global disease damage assessment was higher in the diffuse cutaneous juvenile systemic sclerosis group compared to the limited cutaneous juvenile systemic sclerosis group: 35 and 15 (p = 0.021). Discussion: The majority of this international juvenile systemic sclerosis cohort had diffuse cutaneous juvenile systemic sclerosis (72.5%) with more frequent vascular and pulmonary involvement compared to the limited cutaneous group, who had increased cardiac involvement. Our cohort reflects prior findings of published juvenile systemic sclerosis cohorts and emphasizes a difference in the presentation compared to adult-onset systemic sclerosis.
Authors: E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim Journal: J Rheumatol Date: 1988-02 Impact factor: 4.666
Authors: I Foeldvari; M Zhavania; N Birdi; R J Cuttica; S H de Oliveira; P B Dent; R Elborgh; F Falcini; G Ganser; H Girschick; R Häfner; R Joos; W Kuis; P Pelkonen; A M Prieur; K Rostropowicz-Denisiewicz; R Russo; A Savolainen; A Siamopoulou-Mayridou; F Zulian Journal: Rheumatology (Oxford) Date: 2000-05 Impact factor: 7.580
Authors: Giorgia Martini; Ivan Foeldvari; Ricardo Russo; Ruben Cuttica; Anne Eberhard; Angelo Ravelli; Thomas J A Lehman; Sheila Knupp Feitosa de Oliveira; Gordana Susic; Galina Lyskina; Dana Nemcova; Robert Sundel; Fernanda Falcini; Herman Girschick; Ana Paula Lotito; Antonella Buoncompagni; Flavio Sztajnbok; Sulaiman M Al-Mayouf; Ilonka Orbàn; Clodoveo Ferri; Balu H Athreya; Patricia Woo; Francesco Zulian Journal: Arthritis Rheum Date: 2006-12
Authors: Kenneth Scalapino; Thaschawee Arkachaisri; Mary Lucas; Noreen Fertig; David J Helfrich; Aldo V Londino; Virginia D Steen; Thomas A Medsger Journal: J Rheumatol Date: 2006-04-01 Impact factor: 4.666
Authors: Angela Byun Robinson; Mark F Hoeltzel; Dawn M Wahezi; Mara L Becker; Elizabeth A Kessler; Heinrike Schmeling; Ruy Carrasco; Adam M Huber; Brian M Feldman; Ann M Reed Journal: Arthritis Care Res (Hoboken) Date: 2014-03 Impact factor: 4.794
Authors: Yannick Allanore; Christopher P Denton; Thomas Krieg; Peter Cornelisse; Daniel Rosenberg; Barbara Schwierin; Marco Matucci-Cerinic Journal: Ann Rheum Dis Date: 2016-06-27 Impact factor: 19.103
Authors: Christine Peoples; Thomas A Medsger; Mary Lucas; Bedda L Rosario; Carol A Feghali-Bostwick Journal: J Scleroderma Relat Disord Date: 2016-07-23